BerkiGEM2007 WikiPlaying2

From 2007.igem.org

(Difference between revisions)
Line 1: Line 1:
-
 
Line 54: Line 53:
<body>
<body>
-
<div align="center"><a href="https://2007.igem.org/Berkeley_UC">&lt;&lt;&lt; Return to UC Berkeley iGEM 2007 </a></div>
+
<div align="center">
-
<p align="center"><a href="https://2007.igem.org/BerkiGEM2007Present4">Next Section: Chassis&gt;&gt;</a></p>
+
  <p><a href="https://2007.igem.org/Berkeley_UC">&lt;&lt;&lt; Return to UC Berkeley iGEM 2007 </a></p>
-
<h1 align="center">Engineering Bactoblood for Oxygen Transport<br />
+
  <p> <a href="https://2007.igem.org/BerkiGEM2007Present1">&lt;&lt;Previous Section: Oxygen Transport</a> | <a href="https://2007.igem.org/BerkiGEM2007Present3">Next Section: Controller&gt;&gt;</a></p>
-
</h1>
+
</div>
-
<p align="justify">The primary function of human erythrocytes is to transport oxygen to the body's tissues and remove CO2.  This is accomplished principly by high concentrations of the protein hemoglobinHowever, functional expression of hemoglobin requires the coexpression of the small molecule (heme) that specifically binds oxygen, proteins that promote the expression, folding, and addition of heme to hemoglobin, and proteins that maintain the oxidation state of hemoglobin and prevent the accumulation of toxic oxidizing species in the cellBactoblood will similarly require these activities, so we designed a hierarchical genetic device that encoded this oxygen transport functionOur design contains a heme biosynthesis devices, a hemoglobin generation device, a chaperone device, and a detoxifying deviceAdditionally, we investigated alternatives to hemoglobin that may provide superior oxygen transport to Bactoblood than their human counterpart.</p>
+
<p align="center">&nbsp;</p>
 +
<h1 align="center">The Chassis</h1>
 +
<br />
 +
<p align="justify">There are several core issues associated with introducing <em>E. coli</em> into the bloodstream of human beings or other animals.  First is the issue of sepsis. <em>E. coli</em> possesses a species called lipid X, or endotoxin, in its outer membrane which causes the release of TNFalpha in humans. This is an essential  process of the innate immune system, but high doses of lipid X can be  lethal. Bactoblood must have some ability to avoid this series of events. Similarly, there are a variety of additional features in <em>E. coli</em> that can elicit strong adaptive immune responses including the pili and  flagella. From the bacterium's perspective, the interaction with the  bloodstream is no more desirable. The complement system, another core  component of the innate immune response, can kill bacteria directly.  Additionally, phagocytic cells including macrophages and neutrophils,  can engulf and kill <em>E. coli</em>.  Fortunately for our purposes, there are a variety of modifications we can make to circumvent these problems.</p>
 +
<h2 align="center">The <em>E. coli</em> outer surface</h2>
 +
<p align="justify"><img src="https://static.igem.org/mediawiki/2007/e/e4/BerkiGEM2007-ColiOuterSurface.gif" alt="" width="699" height="475" align="right">To understand these modifications, we must first understand what features are present in <em>E. coli</em> strain MC1061, our starting point for Bactoblood.  Like most strains of <em>E. coli</em> used in the lab, MC1061 comes from the MG1655 lineage and is a "rough"  strain. Unlike other "smooth" strains, MC1061 lacks surface-displayed  capsular polysaccharides known as K capsules and O antigens. It retains  the general 2-membrane architecture present in gram-negative bacteriaIn between these membranes is the periplasmic space which is composed  of a gel-like carbohydrate-rich polymer called peptidoglycan. The inner membrane is composed of a lipid bilayer and a variety of proteins. The  outer membrane similarly is a lipid bilayer, and the lipid component of  it is called lipopolysaccharide, or LPS. The structure of LPS at it's  core is a 6 fatty acid lipid called lipid X. When O antigen polymer chains are present, they are covalently attached to the outer leaf of  LPS. K capsules are similarly embedded in the outer leaf of the outer  membrane, but they are not directly attached to LPS. Other components  of the outer membrane include a structural protein, LPP, and a variety  of other proteins. This outer surface is the critical region of the  bacterium for understanding how it interacts physically with the  outside world. When the bloodstream "looks" at E. coli, what it "sees"  is the outer membrane because everything else is stuck inside.  Modifications such as O antigens and K capsules therefore have dramatic  effects on the bacterium's interactions with the outside world.</p>
<p align="justify">&nbsp;</p>
<p align="justify">&nbsp;</p>
-
<h2 align="center">The Hemoglobin Generating Device</h2>
 
-
<p align="center"><img src="https://static.igem.org/mediawiki/2007/d/d1/Berk-Figure-HbA-HbB.png" name="HemoglobinCassette" width="337" height="111" id="HemoglobinCassette" /><img src="https://static.igem.org/mediawiki/2007/9/9e/Berk-Figure-Map.png" width="251" height="115" alt=""></p>
 
-
<h3 align="center">Overview: Human Hemoglobin A and Methionine Aminopeptidase</h3>
 
-
<p align="justify">The primary component needed for efficient oxygen transport in our  system is human hemoglobin A. (HbA) HbA is a tetramer that consists of  two different subunits, α2β2. We constructed a device that expresses both the alpha (HbA) and beta (HbB) subunits of human hemoglobin A, under the control of a T7 promoter. We also created a similar device that will express mutant versions of human hemoglobin. To cleave the extra methionine residue that is present when expressed in prokaryotic cells, we have also constructed a device which expresses the Map gene, which encodes for methionine aminopeptidase (MetAP). By expressing both of these devices in our system, we achieve the expression of unmodified, fully functional adult human hemoglobin. </p>
 
-
<h3 align="center">Oxygen Binding Affinity and P50</h3>
 
-
<p align="justify">The first problem to be addressed is the insufficiently low P50 of wild type human hemoglobin. The P50 is the partial pressure  of oxygen needed for 50% saturation. A low P50 means that the oxygen affinity is too high, which  inhibits the ability of the hemoglobin to deliver oxygen to the needed tissues.  The P50 for wild type human hemoglobin is ~3.8 torr under normal physiological  conditions, however this varies with temperature and pH.</p>
 
-
<p align="justify"><img src="https://static.igem.org/mediawiki/2007/e/e6/P50Comparison.gif" width="644" height="439" align="left"></p>
 
-
<p align="justify">Demonstrated by George J. Brewer's image to the left, an increase in P50 is the same as shifting the oxygen binding curve to the right. A shift to the right is shown to increase the oxygen transport, thus a higher P50 is desirable for efficient oxygen transport. </p>
 
<p align="justify">&nbsp;</p>
<p align="justify">&nbsp;</p>
-
<p align="justify">In human erythrocytes, the  oxygen binding affinity is decreased by  the presence of an allosteric modifiers, primarily 2,3-diphosphoglycerate (2,3-DPG),  which forces the hemoglobin conformation into the lower affinity deoxy  state, or the T-state. By pushing the hemoglobin into the T-state,  2,3-DPG is effectively pushing any bound oxygen out from the heme center. This effectively lowers the oxygen binding affinity of the hemoglobin and increases the P50. An increase of 0.4mM in  DPG concentration decreases oxygen affinity by about 1.0 torr. Since the  normal concentration of DPG in erythrocytes is ~5mM, this raises the P50 to ~16.3 torr. </p>
 
<p align="justify">&nbsp;</p>
<p align="justify">&nbsp;</p>
-
<p align="justify">DPG isn't the only allosteric modifier of hemoglobin, to a lesser extent, various ions bind to a region near the N-terminal end of the hemoglobin protein and act to increase the P50 as well. In recombinant hemoglobin expressed in E. coli, there is an extra methionine residue at the N-terminal region of expressed proteins. For the case of hemoglobin, that extra methionine acts to inhibit the allosteric effects of certain ions. </p>
+
<h2 align="center">Capsular Polysaccharides</h2>
-
<p align="justify">&nbsp;</p>
+
<p align="center"><img src="https://static.igem.org/mediawiki/2007/e/e4/BerkiGEM2007_O16andK1Clusters.jpg" width="1551" height="267" alt=""></p>
-
<h3 align="center">Wild Type and Mutant Hemoglobins<br />
+
<p align="justify"> The carbohydrates embedded in the outer membrane are extremely diverse within the <em>E. coli</em> species. Both K capsules and O antiens are linear carbohydrates polymer, but at least 150 chemically-distinct O antigens exist in one <em>E. coli</em> strain or another. Similarly, at least 100 chemically-distinct K  capsules have been described. Almost all pathogenic strains of <em>E. coli</em> have some sort of capsular polysaccharide and are referred to as  "smooth" strains. The rough vs. smooth distinction refers to a visibly  discernible quality of their colonies. The particular choice of  carbohydrate present in a bacterium is essential to its ability to  survive in its living environment. For pathogenic and commensal  bacteria, specific O or K carbohydrates are appropriate for distinct  areas of the body (blood stream, urinary tract, intestines) and also  for distinct animal types (birds, pigs, humans, cows, etc.). Over 90% of human cases of <em>E. coli</em> bacteremia (the clinical word for having bacteria in the bloodstream) are caused by strains that have a  specific type of K capsule called K1. K1 is a long linear polymer of sialic acid that extends about half the diameter of the bacterium  beyond its surface. Because polysialic acid is a frequent coating on  mammalian cells, the human immune system does not recognize K1 as  foreign. Bacteria with a K1 capsule are therefore resistant to both  innate and adaptive immune responses. Proper display of a K1 capsule  requires the concomitant expression of any of several O antigens. For  our studies, we have chosen O16. Genetically, the K1 capsule requires  14 genes encoded within a 20kb cassette. The O16 antigen requires 11  genes encoded within a 12kb cassette. Together, these surface  modifications allow the bacterium to avoid detection by the immune  system and should extend the serum half-life of Bactoblood to several  hours rather than the less-than-5 minutes observed with rough strains. Both of these gene clusters have been installed into the genome of MC1061 in the course of preparing our chassis strain, MC828U.</p>
-
</h3>
+
<h2 align="center">Lipid X and its variants</h2>
-
<p align="justify">In our system, we have chosen to use well studied mutants of  human hemoglobin which have been engineered to be permanently in the  deoxy T-state, and the wild type human hemoglobin. The wild type is to compare the mutant hemoglobins to. The first generation Bactoblood blood substitute will use a hemoglobin mutant which has two mutations applied to the beta subunit. The mutations are named Presbyterian (beta-Asn108Lys) and providence (beta-Lys82Asp). It has been reported that human hemoglobin with these two point mutations has a P50 in the range of ~44 torr, an acceptable P50 value for a good blood substitute.</p>
+
<div align="justify">The lipid X component of the LPS in <em>E. coli</em> contains 6 acyl  chains. Mammalian blood contains a protein called LBP that scavenges  this molecule from both live and lysed bacteria and transfers it to  toll-like receptor 4 present on mammalian cells. These events initiate  a signal transduction cascade resulting in the release of a protein  called TNFalpha. The inflammatory response to these events at low doses  helps your body fight off bacterial infections. At higher doses, it can  result in organ failure and even death. The lipid X moiety present in a  variety of other bacteria do not initiate this cascade of events. Similarly, a pentaacylated variant of the <em>E. coli</em> lipid X is  1000x less agonistic of this response. Our bacteria synthesize this  pentaacylated variant due to the deletion of the gene responsible for  attaching the sixth acyl chain, <em>msbB</em>.
-
<p align="justify">The western blot to the bottom shows various mutant hemoglobins we constructed and tested for hemoglobin yield. A polyclonal antibody was used to identify the produced hemoglobin. All of these samples had heme added exogenously to the culture during growth and were allowed to grow overnight. The bands around 16kD are consistent with monomeric alpha and beta subunits of hemoglobin. Some of the constructs contain a fusion of alpha subunits with a glycine linker. More about this will be discussed in the hemoglobin solubility section. The western demonstrates that hemoglobin is being produced in our cells to a significant degree. In our potential final product, the heme will be produced in vivo and our cultures will be concentrated. This will greatly increase the concentration of hemoglobin in our cells to hopefully near physiological concentrations. </p>
+
</div>
-
<h3 align="center"><img src="https://static.igem.org/mediawiki/2007/b/bc/Westernpicture.jpg" width="725" height="871" border="0" align="middle"></h3>
+
<h2 align="center">Additional cell-surface epitopes</h2>
-
<h3 align="center">Methionine Aminopeptidase</h3>
+
<div align="justify">Essentially any component on the surface of the bacteria has the  potential to elicit either innate or adaptive immune responses. Of  those present on MC1061's surface, type I pili and flagella are known  to elicit such responses. Each of these features is encoded within  multi-gene operons encoding protein assemblies that extend out from the  bacteral surface. Type I pili allow bacteria to adhere to the surface  of mammalian cells. Flagella are the "propellers" that allow the  bacteria to swim during chemotaxis. Bactoblood does not require either  of these activities, so these genes were deleted in the chassis strain. </div>
-
<p align="justify">In prokaryotic cells, the N-terminal end of proteins retain the initial methionine residue from translation. In order to create human hemoglobin in the same form as it exists in erythrocytes, this extra methionine needs to be cleaved. The enzyme that does this occurs natrually in prokaryotes and is called methionine aminopeptidase (MetAP), encoded for by the Map gene. However, recombinant hemoglobin largely retains this extra methionine residue. By overexpressing metAP, it has been shown that a large percentage of the produced hemoglobin can be free of this extra methionine residue. It has also been shown that removal of the extra methionine residue increases the P50 slightly.</p>
+
<h2 align="center">Growth control by iron restriction</h2>
-
<p align="justify">&nbsp;</p>
+
<div align="justify">A critical challenge in the development of Bactoblood is the ability to  safely inject a large quantity of bacteria into the bloodstream. It is essential that these bacteria do not grow for a safe administration. We have adopted a two-tier strategy for eliminating the possibility of growth. First, we make our bacteria unable to grow in the bloodstream  due to their inability to acquire a specific nutrient, iron. Secondly, we introduce a genetic kill switch device that destroys the bacterium's  DNA once it has produced all the necessary biochemical components  needed to carry oxygen. <em>E. coli</em> can acquire iron by either  high-affinity or low-affinity iron transport. When they grow in LB  media, they use low-affinity transport which involves specific  membrane-embedded transporters that can pump in free iron ions. In  animal body fluids, the concentration of these ions is less than 10-15  molar. The iron is sequestered in small molecule chelators such as heme  or proteins like transferrin and ferritin. Acquiring iron in such an  environment requires more elaborate processes involving secreted  chelators that can grab the iron from these proteins. These processes,  collectively referred to as high-affinity iron transport, all require  the function of <em>tonB</em>.  By deleting <em>tonB</em> in our chassis  organism, we obtain a strain that retains its ability to grow normally  in LB media but is unable to grow in mammalian body fluids.
-
<h2 align="center">The Chaperone Device</h2>
+
</div>
-
<p align="center"><img src="https://static.igem.org/mediawiki/2007/a/aa/Berk-Figure-AHSP.png" width="257" height="122" /></p>
+
<h2 align="center">Characterization of the chassis, MC828U</h2>
-
<h3 align="center">Overview: Alpha Hemoglobin Stabilizing Protein</h3>
+
<p align="justify">The genotype of our chassis organism is: </p>
-
<p>Alpha hemoglobin stabilizing protein (AHSP) is a chaperone protein normally found in erythrocytes. Because AHSP is important in the proper folding of hemoglobin, we created a device under a T7 promoter which will express AHSP in Bactoblood. </p>
+
<div align="justify">
-
<h3 align="center"><img src="https://static.igem.org/mediawiki/2007/b/b0/AHSPreaction.png" width="636" height="476" align="left"></h3>
+
  <pre><strong>MC828U</strong> delta(<em>araA</em>-<em>leu</em>)7697 <em>araD139</em> delta(<em>codB</em>-<em>lac</em>)=delta<em>lac74</em> <em>galK16</em>  <em>
-
<h3 align="center">Hemoglobin Solubility</h3>
+
galE15</em> <em>mcrA0</em> <em>relA1</em> <em>rpsL150</em> <em>spoT1</em> <em>mcrB9999</em> <em>hsdR2</em> O16(delta<em>wbbL</em>) 
-
<p>The alpha subunit of hemoglobin is more prone to precipitation because an alpha-alpha dimer is insoluble under normal conditions. This can cause an excess of beta subunits and decreased output of functional tetrameric hemoglobin. In order to prevent alpha subunits from binding to themselves and precipitating out of solution, human erythrocytes contain an alpha hemoglobin stabilizing protein (AHSP), which acts as a chaperone. AHSP has the ability to bind to the alpha subunit of hemoglobin while keeping it soluble. The AHSP bound alpha subunit readily gives up its AHSP for a beta subunit which then goes on to form functional tetrameric hemoglobin. By expressing AHSP in Bactoblood, we expect to increase the yield of functional, soluble tetrameric hemoglobin. The mechanism for AHSP is shown in the figure to the left. </p>
+
K1(delta<em>neuS</em>) delta<em>msbB</em> delta<em>fim</em> delta<em>tonB</em> delta<em>flhCD</em>  <em>
-
<p><br />
+
upp</em>::(Ptet-<em>wbbL</em>-<em>neuS</em>)  </pre>
-
</p>
+
</div>
-
<p align="justify">&nbsp;</p>
+
<p align="justify">To illustrate the function of our chassis, here we show the function  of 2 critical features of chassis: its ability to survive in serum and  loss of chemotaxis due to the deletion of flagella. </p>
-
<p align="justify">&nbsp;</p>
+
<p align="justify"><br>
-
<p align="justify">In addition, we have also explored a fusion of  di-alpha subunits with a glycine linker. This has been shown to give a  higher soluble output by  stabilizing the alpha subunits and  preventing precipitation. </p>
+
  The serum assay shows the chassis' ability to survive in serum due to its K1:O16 additions and msbB deletion.</p>
-
<p align="justify"><br />
+
<p><img src="https://static.igem.org/mediawiki/2007/9/9c/Serumassaypic.jpg" alt="" width="835" height="685" align="middle"></p>
-
</p>
+
-
<h2 align="center">Heme Biosynthesis Device</h2>
+
-
<p align="center"><img src="https://static.igem.org/mediawiki/2007/f/fd/Berk-Figure-hemABCD.png" width="563" height="122" /></p>
+
-
<h3 align="center">Overview: Heme</h3>
+
-
<p align="justify">Heme is a prosthetic group to hemoglobin. Heme consists of  an iron atom surrounded by a porphyrin ring. Each hemoglobin tetramer  is capable of binding up to four heme groups. One of the most important  functions of heme, and the fuction we are interested in, is to assist in the transportation of diatomic gases, namely oxygen. The heme biosynthesis pathway is already present in E. coli, however, to achieve the high concentrations of functional hemoglobin needed for Bactoblood, we need lots of heme. We have constructed a device containing thefour genes hemA, hemB, hemC, and hemD. These genes are the primary bottlenecks in the heme biosynthesis pathway. We hope to greatly increase the production of heme by overexpressing these four genes under a T7 promoter. </p>
+
-
<h3 align="center"><strong>Heme Biosynthesis Pathway</strong> </h3>
+
-
<p>The biosynthetic pathway contains primarily eight enzymes.  We  included  hemA (Delta-aminolevulinate synthase), hemB  (Delta-aminolevulinic acid dehydratase), hemC (porphobilinogen  deaminase), and hemD (uroporphyrinogen III synthase) in our system. These genes overproduce <em>precursors</em> to heme in our cells because over-accumulation of heme itself  would result in toxicity. After  successful subcloning experiments, the bacterial cell pellets would  become reddish-brown due to the accumulation of porphyrins and heme.</p>
+
-
<p><img src="https://static.igem.org/mediawiki/2007/0/01/96wellplateheme.jpg" width="498" height="308" align="left"></p>
+
-
<h3 align="center">Construction of the Heme Device</h3>
+
-
<p>The hemA gene was cloned from both R.capsulatus and  CFT073. Both were cloned to figure out which versin would give a greater yield of heme precursors. We also cloned hemB, hemC, and hemD from MG1655. We attached single ribosomal binding sites to the genes, and we also attached a library of ribosomal  binding sites to the genes. We used a library of ribosome binding sites so that we could grow up many clones in a 96 well plate and determine which ribosome binding sites were the strongest. The image of such a 96 well plate is shown to the left. Because  colors change is a phenotype of  porphyrins and heme, it was easy to select single colonies that  corresponded to the stronger ribosomal binding sites in library.  These stronger clones would yield the greatest amount of heme and heme precursors and have  the deepest red/brown color of all the clones. </p>
+
-
<p><br>
+
-
</p>
+
<p>&nbsp;</p>
<p>&nbsp;</p>
-
<h3 align="center"><img src="https://static.igem.org/mediawiki/2007/9/9b/Hemespec.jpg" width="681" height="426" align="right"></h3>
+
<p>In a swarming assay done to demonstrate the effect of flagella deletion, the wildtype MC1061 cells on the left plate were able to swim out much farther than those of the MC828U chassis, shown on the right plate.</p>
-
<h3 align="center">Verification of the Heme Device</h3>
+
<p align="justify"><img src="https://static.igem.org/mediawiki/2007/f/f3/SwarmingPic.jpg" alt="" width="492" height="272" align="middle"></p>
-
<p>With our construct complete, we employed UV-Vis to confirm that the red product we are seeing is, in fact, heme. The maximum absorbance for  heme occurs at 412 nm. The graph to the right verifies that by alleviating the bottlenecks in the heme biosynthesis pathway, we have increased the concentration of heme in our system.</p>
+
-
<p>&nbsp;</p>
+
-
<p>&nbsp;</p>
+
-
<p>&nbsp;</p>
+
-
<p>&nbsp;</p>
+
-
<p>&nbsp;</p>
+
-
<p>&nbsp;</p>
+
-
<p>&nbsp;</p>
+
-
<h2 align="center">Autoxidation Control<br />
+
-
</h2>
+
-
<p align="center"><img src="https://static.igem.org/mediawiki/2007/7/7b/Berk-Figure-Cytochrome.png" width="582" height="112" /><img src="https://static.igem.org/mediawiki/2007/4/40/Berk-Figure-SodC-katG.png" width="294" height="105" /></p>
+
-
<h3 align="center">Overview: Cytochromes and Antioxidants</h3>
+
-
<p align="justify">During the process of binding and unbinding oxygen, the heme  groups of the hemoglobin may spontaneously undergo autoxidation, ultimately causing the formation of damaging free radicals and changing the form of the iron in the heme center. To remedy these problems we created an antioxidant device and a methemoglobin reductase device. The antioxidant device contains the genes that express superoxide dismutase and catalase. The methemoglobin reductase device contains the genes that express cytochrome b5 and cytochrome b5 reductase. These two devices will keep our hemoglobin functional and our cells healthy. </p>
+
-
<h3 align="center">Autoxidation and Free Radical Production</h3>
+
-
<p align="justify">There are two problems to address in keeping our cells happy and our hemoglobin functional. The first problem is the spontaneous autoxidation of the heme centers in hemoglobin. During the binding and unbinding of oxygen, electrons are transfered back and forth between the iron center of heme and the bound oxygen molecule. Every once in a while, an electron will transfer to the oxygen and the oxygen will then unbind from the iron center and take the electron away from the iron. This creates a superoxide and a ferric Fe3+ heme. The superoxide eventually will degrate into a hydrogen peroxide, then into a hydroxyl radical, which is very toxic to the cell. The second problem is that the ferric heme can no longer bind oxygen, leaving the hemoglobin non-functional, this form is also known as methemoglobin. This autoxidation occurs on the order of hours, therefore accumulation of non-functional methemoglobin is significant if left alone. </p>
+
-
<h3 align="center"><img src="https://static.igem.org/mediawiki/2007/8/87/Antioxidantreactions.jpg" width="528" height="403" align="left"></h3>
+
-
<h3 align="center">Antioxidants</h3>
+
-
<p align="justify">Erythrocytes remedy the problem of free radical accumulation and damage by containing the antioxidant enzymes catalase and superoxide  dismutase. These enzymes catalyze the breakdown of superoxide into  oxygen and H2O. These enzymes are already used in E. Coli because free radicals are formed regularly during metabolism. However, we feel that because of our unusual accumulation of heme and hemoglobin, we must supplement the breakdown of the formed superoxides by overexpressing the catalase and superoxide dismutase genes in our system. The reaction mechanism to the left shows the pathway of superoxide degredation and the roles of superoxide dismutase and catalase. The desired breakdown of superoxide is through the two enzymes mentioned. The alternative pathway results in more non-functional ferric iron. </p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp; </p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<h3 align="center"><img src="https://static.igem.org/mediawiki/2007/3/3c/Cytochromereactions.jpg" width="500" height="426" align="right"></h3>
+
-
<h3 align="center">Cytochrome b5 / Cytochrome b5 Reductase and Methemoglobin</h3>
+
-
<p align="justify"> Human erythrocytes have addressed the accumulation of methemoglobin caused by the autoxidation  problem by using the NADH dependent enzyme, cytochrome b5 reductase. Working together with cytochrome b5, these two components allow for reduction of the methemoglobin heme centers back into its functional ferrous (Fe2+) form. The mechanism is shown to the right. </p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<p align="justify"><br />
+
-
</p>
+
-
<p align="justify">&nbsp;</p>
+
-
<h2 align="center">Hemoglobin Alternatives</h2>
+
-
<p align="justify">We also investigated two alternatives to the hemoglobin part in our  device: H-NOX and Myoglobin. Although the intrinsic oxygen-carrying  ability of these proteins is different from Hemoglobin, variants of  these proteins have been engineered with similar P50 values. These variants might allow Bactoblood to carry more oxygen than hemoglobin. </p>
+
-
<p align="justify">H-NOX is a heme-based sensor that is found in bacteria. H-NOX is  able to bind Oxygen using a distal pocket tyrosine. For this gene I  added the T7 promoter we created for this project, an RBS site, and  lastly a Bca1092 terminator. When we assayed this part the results were  inconclusive. The part was assembled correctly but the assay didn't  show strong signs of expression. </p>
+
-
<p align="justify">The second gene we explored was Sperm Whale Myoglobin.  Myoglobin is a monomeric protein that behaves as an intracellular  oxygen storage site. Sperm whale myoglobin in particular is easily  found in large amounts in the whale's muscle tissue. The construction  of this part was very similar to that of the H-NOX composite part. It  used the same promoter, terminator, and RBS. The assay for Myoglobin  showed a bit more promise but couldn't conclusively show that Myoglobin  was binding to oxygen. </p>
+
-
<div align="center"><a href="https://2007.igem.org/Berkeley_UC">&lt;&lt;&lt; Return to UC Berkeley iGEM 2007 </a></div>
+
-
<p align="center"><a href="https://2007.igem.org/BerkiGEM2007Present4">Next Section: Chassis&gt;&gt;</a></p>
+
</body>
</body>
</html>
</html>

Revision as of 21:39, 26 October 2007


Untitled Document

<<< Return to UC Berkeley iGEM 2007

<<Previous Section: Oxygen Transport | Next Section: Controller>>

 

The Chassis


There are several core issues associated with introducing E. coli into the bloodstream of human beings or other animals. First is the issue of sepsis. E. coli possesses a species called lipid X, or endotoxin, in its outer membrane which causes the release of TNFalpha in humans. This is an essential process of the innate immune system, but high doses of lipid X can be lethal. Bactoblood must have some ability to avoid this series of events. Similarly, there are a variety of additional features in E. coli that can elicit strong adaptive immune responses including the pili and flagella. From the bacterium's perspective, the interaction with the bloodstream is no more desirable. The complement system, another core component of the innate immune response, can kill bacteria directly. Additionally, phagocytic cells including macrophages and neutrophils, can engulf and kill E. coli. Fortunately for our purposes, there are a variety of modifications we can make to circumvent these problems.

The E. coli outer surface

To understand these modifications, we must first understand what features are present in E. coli strain MC1061, our starting point for Bactoblood. Like most strains of E. coli used in the lab, MC1061 comes from the MG1655 lineage and is a "rough" strain. Unlike other "smooth" strains, MC1061 lacks surface-displayed capsular polysaccharides known as K capsules and O antigens. It retains the general 2-membrane architecture present in gram-negative bacteria. In between these membranes is the periplasmic space which is composed of a gel-like carbohydrate-rich polymer called peptidoglycan. The inner membrane is composed of a lipid bilayer and a variety of proteins. The outer membrane similarly is a lipid bilayer, and the lipid component of it is called lipopolysaccharide, or LPS. The structure of LPS at it's core is a 6 fatty acid lipid called lipid X. When O antigen polymer chains are present, they are covalently attached to the outer leaf of LPS. K capsules are similarly embedded in the outer leaf of the outer membrane, but they are not directly attached to LPS. Other components of the outer membrane include a structural protein, LPP, and a variety of other proteins. This outer surface is the critical region of the bacterium for understanding how it interacts physically with the outside world. When the bloodstream "looks" at E. coli, what it "sees" is the outer membrane because everything else is stuck inside. Modifications such as O antigens and K capsules therefore have dramatic effects on the bacterium's interactions with the outside world.

 

 

 

Capsular Polysaccharides

The carbohydrates embedded in the outer membrane are extremely diverse within the E. coli species. Both K capsules and O antiens are linear carbohydrates polymer, but at least 150 chemically-distinct O antigens exist in one E. coli strain or another. Similarly, at least 100 chemically-distinct K capsules have been described. Almost all pathogenic strains of E. coli have some sort of capsular polysaccharide and are referred to as "smooth" strains. The rough vs. smooth distinction refers to a visibly discernible quality of their colonies. The particular choice of carbohydrate present in a bacterium is essential to its ability to survive in its living environment. For pathogenic and commensal bacteria, specific O or K carbohydrates are appropriate for distinct areas of the body (blood stream, urinary tract, intestines) and also for distinct animal types (birds, pigs, humans, cows, etc.). Over 90% of human cases of E. coli bacteremia (the clinical word for having bacteria in the bloodstream) are caused by strains that have a specific type of K capsule called K1. K1 is a long linear polymer of sialic acid that extends about half the diameter of the bacterium beyond its surface. Because polysialic acid is a frequent coating on mammalian cells, the human immune system does not recognize K1 as foreign. Bacteria with a K1 capsule are therefore resistant to both innate and adaptive immune responses. Proper display of a K1 capsule requires the concomitant expression of any of several O antigens. For our studies, we have chosen O16. Genetically, the K1 capsule requires 14 genes encoded within a 20kb cassette. The O16 antigen requires 11 genes encoded within a 12kb cassette. Together, these surface modifications allow the bacterium to avoid detection by the immune system and should extend the serum half-life of Bactoblood to several hours rather than the less-than-5 minutes observed with rough strains. Both of these gene clusters have been installed into the genome of MC1061 in the course of preparing our chassis strain, MC828U.

Lipid X and its variants

The lipid X component of the LPS in E. coli contains 6 acyl chains. Mammalian blood contains a protein called LBP that scavenges this molecule from both live and lysed bacteria and transfers it to toll-like receptor 4 present on mammalian cells. These events initiate a signal transduction cascade resulting in the release of a protein called TNFalpha. The inflammatory response to these events at low doses helps your body fight off bacterial infections. At higher doses, it can result in organ failure and even death. The lipid X moiety present in a variety of other bacteria do not initiate this cascade of events. Similarly, a pentaacylated variant of the E. coli lipid X is 1000x less agonistic of this response. Our bacteria synthesize this pentaacylated variant due to the deletion of the gene responsible for attaching the sixth acyl chain, msbB.

Additional cell-surface epitopes

Essentially any component on the surface of the bacteria has the potential to elicit either innate or adaptive immune responses. Of those present on MC1061's surface, type I pili and flagella are known to elicit such responses. Each of these features is encoded within multi-gene operons encoding protein assemblies that extend out from the bacteral surface. Type I pili allow bacteria to adhere to the surface of mammalian cells. Flagella are the "propellers" that allow the bacteria to swim during chemotaxis. Bactoblood does not require either of these activities, so these genes were deleted in the chassis strain.

Growth control by iron restriction

A critical challenge in the development of Bactoblood is the ability to safely inject a large quantity of bacteria into the bloodstream. It is essential that these bacteria do not grow for a safe administration. We have adopted a two-tier strategy for eliminating the possibility of growth. First, we make our bacteria unable to grow in the bloodstream due to their inability to acquire a specific nutrient, iron. Secondly, we introduce a genetic kill switch device that destroys the bacterium's DNA once it has produced all the necessary biochemical components needed to carry oxygen. E. coli can acquire iron by either high-affinity or low-affinity iron transport. When they grow in LB media, they use low-affinity transport which involves specific membrane-embedded transporters that can pump in free iron ions. In animal body fluids, the concentration of these ions is less than 10-15 molar. The iron is sequestered in small molecule chelators such as heme or proteins like transferrin and ferritin. Acquiring iron in such an environment requires more elaborate processes involving secreted chelators that can grab the iron from these proteins. These processes, collectively referred to as high-affinity iron transport, all require the function of tonB. By deleting tonB in our chassis organism, we obtain a strain that retains its ability to grow normally in LB media but is unable to grow in mammalian body fluids.

Characterization of the chassis, MC828U

The genotype of our chassis organism is:

MC828U delta(araA-leu)7697 araD139 delta(codB-lac)=deltalac74 galK16   
galE15 mcrA0 relA1 rpsL150 spoT1 mcrB9999 hsdR2 O16(deltawbbL)   
K1(deltaneuS) deltamsbB deltafim deltatonB deltaflhCD   
upp::(Ptet-wbbL-neuS)  

To illustrate the function of our chassis, here we show the function of 2 critical features of chassis: its ability to survive in serum and loss of chemotaxis due to the deletion of flagella.


The serum assay shows the chassis' ability to survive in serum due to its K1:O16 additions and msbB deletion.

 

In a swarming assay done to demonstrate the effect of flagella deletion, the wildtype MC1061 cells on the left plate were able to swim out much farther than those of the MC828U chassis, shown on the right plate.